Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enveric Biosciences Inc (NQ: ENVB ) 0.4710 -0.0080 (-1.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enveric Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally July 25, 2024 Via Benzinga Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally July 25, 2024 From Enveric Biosciences Via Business Wire Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement July 15, 2024 From Enveric Biosciences Via Business Wire New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies July 11, 2024 Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. Via Benzinga Topics Intellectual Property Exposures Intellectual Property Enveric Biosciences Announces Patent Granted for Drug Candidate July 10, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate June 25, 2024 From Enveric Biosciences Via Business Wire Enveric Biosciences to Participate in BIO International Convention 2024 May 30, 2024 From Enveric Biosciences Via Business Wire ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024 May 20, 2024 ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand May 16, 2024 Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... Via Benzinga Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results May 15, 2024 From Enveric Biosciences Via Business Wire Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate May 14, 2024 Via Benzinga Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders May 14, 2024 From Enveric Biosciences Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 08, 2024 Via Benzinga Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods May 08, 2024 The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance. Via Benzinga Topics Cannabis Exposures Cannabis Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids May 08, 2024 From Enveric Biosciences Via Business Wire Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session April 03, 2024 Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... Via Benzinga Exposures Glyphosate 12 Health Care Stocks Moving In Wednesday's Pre-Market Session April 03, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session April 02, 2024 Via Benzinga ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 April 01, 2024 ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth March 27, 2024 Via Benzinga Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 March 26, 2024 From Enveric Biosciences Via Business Wire Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates 12 Health Care Stocks Moving In Tuesday's After-Market Session March 19, 2024 Via Benzinga Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga Nasdaq Down 100 Points; US Housing Starts Surge In February March 19, 2024 U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell... Via Benzinga Topics Stocks Exposures US Equities Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday? March 19, 2024 Enveric Biosciences announces significant progress with non-binding term sheets signed with a biotech firm for cannabinoid-COX-2 conjugate compounds, targeting joint diseases. These agreements could... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 19, 2024 Via Benzinga Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease March 19, 2024 From Enveric Biosciences Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.